Onconetix Inc
ONCO
NASDAQ
Biotechnology
$0.81
USD
-0.07 (-8.06%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.48M
Volume 232.1K
About Onconetix Inc
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 2 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
CEO
Ms. Karina Fedasz
HQ
Cincinnati, OHIO, US
Founded
2022
Employees
5
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on ONCO.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-61.8%
—
Gross Margin (TTM)
79.6%
+32.3 pp
Operating Margin (TTM)
-2109.9%
+901.4 pp
Net Margin (TTM)
-1319.6%
+1595.2 pp
ROE (TTM)
-82.6%
+1322.9 pp
Free Cash Flow (TTM)
$-9.80M
—
Financial Snapshot
Revenue
$735,198
-61.8%
YoY
Gross Margin
80%
TTM
+68.1%
YoY
Net Income
$-9.70M
+82.7%
YoY
Operating Cash Flow
$-9.80M
-34.9%
YoY
Key Statistics
Open
$0.88
Previous Close
$0.88
Day Range
$0.81 - $0.88
52 Week Range
$0.67 - $209.50
Volume
232.1K
Average Volume (10 Days)
170.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$3.48M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
4.73
Price / Book
0.30
Financial Highlights
Profit Margin
-1319.6%
Return on Assets
-65.4%
Return on Equity
-82.6%
Revenue (TTM)
$735,198
Net Income (TTM)
$-9.70M
Diluted EPS (TTM)
-$436.33
Total Cash (MRQ)
$3.72M
Levered FCF (TTM)
$-9.80M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
